Unveiling the Potential Drug Target and Biomarker suGT1P4-STRA6LP-CCDC180: A Promising Target for Cancer Treatment

Target Name: SUGT1P4-STRA6LP-CCDC180

NCBI ID: G57653

SUGT1P4-STRA6LP-CCDC180

Unveiling the Potential Drug Target and Biomarker suGT1P4-STRA6LP-CCDC180: A Promising Target for Cancer Treatment

SUGT1P4-STRA6LP-CCDC180 is a variant gene that has recently been identified as a potential drug target and biomarker for cancer treatment. This gene is located on chromosome 17 and encodes for a protein known as STRA6LP, which plays a critical role in cell signaling pathways. The variant form of STRA6LP found in suGT1P4-STRA6LP-CCDC180 has been shown to have altered gene expression and post-transcriptional modifications, which may pave the way for new therapeutic approaches in cancer treatment.

The Identification of suGT1P4-STRA6LP-CCDC180 as a Drug Target

SUGT1P4-STRA6LP-CCDC180 has been identified as a potential drug target due to its unique expression pattern in various cancer types. The expression of STRA6LP has been shown to be increased in various cancer tissues, including breast, ovarian, and colorectal cancer. Additionally, the expression of STRA6LP has been associated with cancer-related survival in animal models.

The potential drug targets for STRA6LP include inhibiting its expression or modifying its function to reduce its impact on cancer cell growth and survival. Currently, there are limited therapeutic options for cancer treatment that specifically target STRA6LP. The identification of suGT1P4-STRA6LP-CCDC180 as a potential drug target opens up new avenues for cancer research and development.

The Potential of suGT1P4-STRA6LP-CCDC180 as a Biomarker

The expression of STRA6LP has also been shown to be associated with cancer-related biomarkers, including the expression of the protein PD-L1. PD-L1 is a known cancer stem cell antigen (CSCA) and has been shown to promote cancer cell survival and proliferation. The identification of suGT1P4-STRA6LP-CCDC180 as a potential biomarker for cancer detection and treatment is a promising development for cancer research.

The expression of PD-L1 has been shown to be increased in various cancer tissues and has been associated with cancer-related survival. The potential use of PD-L1 as a biomarker for cancer detection and treatment has led to the development of new diagnostic tests and therapeutic approaches. The identification of suGT1P4-STRA6LP-CCDC180 as a potential biomarker for cancer detection opens up new avenues for cancer research and development.

Conclusion

The identification of suGT1P4-STRA6LP-CCDC180 as a potential drug target and biomarker for cancer treatment is a promising development in cancer research. The alteration in gene expression and post-transcriptional modifications associated with the variant form of STRA6LP make it an attractive target for small molecule inhibitors. Additionally, the potential use of PD-L1 as a biomarker for cancer detection and treatment adds a new dimension to cancer research. Further studies are needed to determine the efficacy and safety of targeting STRA6LP with small molecules and to develop new diagnostic tests for cancer detection.

Protein Name: SUGT1P4-STRA6LP-CCDC180 Readthrough

The "SUGT1P4-STRA6LP-CCDC180 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SUGT1P4-STRA6LP-CCDC180 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets